A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder.

Trial Profile

A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Bevacizumab; Cisplatin; Gemcitabine; Paclitaxel
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top